Some NSCLC patients, who burden the mutation of epidermal growth factor receptor (EGFR), have pointers to the target therapy [22] and may also have poor therapeutic effect due to high BACH1 expression. The gene discussed is BACH1; the disease is non-small cell lung carcinoma.